SAN DIEGO, CA – Invetech, a global leader in instrument design and development, custom automation, and contract manufacturing, and NanoCellect Biomedical, a company developing affordable and accessible flow cytometry and cell sorting technology for life science researchers, today announced a collaboration to develop a novel flow cytometry platform.
Headquartered in San Diego, NanoCellect Biomedical has developed a microchip-based cell sorting technology. NanoCellect’s flow cytometry platform combines multiple innovations that provide fluorescence detection, sorting safety, economy, and portability—creating access to personal flow cytometers. The company’s first product, the WOLF™ Cell Sorter, uses a closed fluid-path microfluidic cartridge that enables easy-to-use cell sorting and avoids biohazard and shear stress issues associated with traditional cell sorters. Based on this innovative flow cytometry platform, the technology enables cell analysis and sorting within a disposable chip and instantaneous feedback of sorting accuracy. The company has been awarded several NIH grants that have supported development of the WOLF™ Cell Sorter technology and that have positioned the company to expand its technology pipeline and engage Invetech as a development partner to assist in the development of a Point of Care (POC) cancer diagnostics platform.
Jose Morachis, NanoCellect CEO, said, “With a team based right here in San Diego and extensive experience that relates directly to our WOLF™ Cell Sorter platform, Invetech is the ideal partner to help us advance our product development efforts moving forward. Their expertise in both development strategy and production will ensure seamless integration to help us achieve our aggressive goals in both innovation and project timelines.”
“While we work with companies all around the world, our presence in San Diego can present important advantages by providing ongoing opportunities for in-person collaboration and strategy development. In addition, our experience supporting novel technologies such as NanoCellect’s POC diagnostic platform means that we can hit the ground running in our work with NanoCellect,” said David James, global vice president diagnostics at Invetech. “We especially enjoy helping companies at all stages, from start-ups to global leaders in technology, to address critically important challenges, particularly in the molecular diagnostics and personalized medicine spaces. We look forward to putting our experience to work for NanoCellect.”
NanoCellect Biomedical plans to exhibit the WOLF™ Cell Sorter technology at CYTO 2015, the annual Congress of the International Society for the Advancement of Cytometry, being held June 26-30 at the Scottish Exhibition and Conference Centre in Glasgow, Scotland. The WOLF™ Cell Sorter technology platform will initially be available only for research use, with the potential to be used in a broad range of commercial diagnostics or cell therapy applications in the near future.